From Test to Treatment: Closing the Final Mile in Patient Care
Scott Phillips
From Test to Treatment: Closing the Final Mile in Patient Care
Diagnostic testing has changed how we detect disease. It provides earlier insights and helps identify more targeted treatment options in patient care. But even when a diagnostic test or biomarker result points to a clear treatment path, patients can still face delays in getting the care they need.
A Confidence Gap at the Point of Care
Diagnostic and biomarker tests are widely available. However, many physicians struggle to interpret complex biomarker results. This uncertainty can delay treatment decisions and create challenges in patient care. Webinars and static resources often fail to support clinicians when they need answers most.
The impact is significant: up to 64% of eligible patients are lost along the treatment pathway (Sadik et al., JCO 2022). This is more than a communication gap. It is a missed opportunity to improve patient outcomes.
The Power of Early Detection
As Dr. Michelle Shiller noted in our recent webinar:
“We are ultimately going to win this war on cancer from a testing perspective... detecting cancer early stage, more and more, that is the best hope for a cure.”
Early detection is a powerful first step. But test results only create value when they lead to timely decisions and action in patient care.
Uncertainty among physicians remains a challenge. In primary care, diagnostic uncertainty can lead to stress and defensive practices. For example, physicians may order additional tests or delay treatment decisions (Alam et al., BMC Primary Care, 2017). Research also shows that healthcare professionals may lack confidence when making complex prescribing decisions (Woit et al., IJPP, 2020).
A New Model for Real-Time Support
Closing this gap requires support that is available when clinicians need it most. DXRX Expert Exchange provides peer-to-peer, just-in-time support in patient care.
It connects treating physicians with expert pathologists within 48 hours of a test result. This helps clinicians understand biomarker findings, make confident decisions, and provide timely care.
The outcomes speak for themselves:
- 86% engagement rate
- 89% of healthcare professionals report improved understanding of biomarker utility
- Demonstrated changes in real-world prescribing behavior
Data insights sourced from Diaceutics’ client projects
Turning Insight into Action
Timely education, smart alerts, and personalized support help physicians act on test results. DXRX Signal, Physician Engage, and Expert Exchange help clinicians make informed decisions.
By closing the gap between testing and treatment, we improve patient care and outcomes.
Talk to our experts today about improving treatment pathways and patient care.
About Diaceutics
We’ve been with pharma and biotech companies for over 20 years, helping them to make more informed diagnostic and therapeutic decisions based on real-world data. Our platforms and tools provide global insight from a network of laboratories across 50+ countries.
This unparalleled visibility into real-world testing helps support therapy programs across oncology, cardiology, neurology, autoimmune, rare diseases, and many more.
Why don't traditional blockbuster commercialization models work for precision medicine?
Traditional blockbuster models are built for broad patient populations, relying on large sales teams and wide-reaching campaigns. Precision therapies target specific biomarkers and smaller patient groups, meaning these broad models are often too costly and fail to reach physicians at the exact moment treatment decisions are being made.
Why do precision medicines sometimes get deprioritized or abandoned despite strong clinical results?
Promising precision therapies are sometimes deprioritized, abandoned or returned to licensors, not because of clinical shortcomings, but because traditional commercial models can't financially or operationally support their targeted nature. This often happens when diagnostic testing lags behind drug launch and pharma, labs and physicians fail to collaborate early.
Why does diagnostic testing need to be aligned with drug launch timing?
Diagnostic testing is often assumed to naturally follow a drug launch, but in practice it can lag significantly, causing eligible patients to be missed. Early collaboration between pharma, diagnostic labs and physicians is essential to ensure testing infrastructure is ready to identify the right patients when a therapy becomes available.
What is Targeted Commercialization and how does it differ from traditional models?
Targeted Commercialization is an approach pioneered by Diaceutics that matches the precision of modern therapies with an equally precise commercial strategy. Rather than relying on broad sales campaigns, it uses real-world data, persona-driven engagement, and flexible pricing to connect new treatments with the right patients at the right time.
How does real-world data support precision medicine commercialization?
Real-world data reveals what is actually happening across testing and treatment in real time, including where diagnostic testing gaps remain. This allows commercial teams to identify where patients may be missed and respond with timely, targeted engagement rather than relying on assumptions about testing uptake.
What is persona-driven engagement in precision medicine commercialization?
Written By Scott Phillips
References
- Reference example
Newsletter sign up
READY TO DO COMMERCIALIZATION DIFFERENTLY?
You might also be interested in?
Amplifying Your Precision Medicine Strategy: The role of Engagement Experts and Peer Networks
Enhance your precision medicine strategy through multi-modal communications and peer engagement, driving effective diagnostic commercialization and maximizing patient outcomes.